
Ned Pagliarulo
Lead Editor | @NedPagliaruloNed is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from the College at Georgetown University.
2243 articles by Ned Pagliarulo
-
FDA approves cancer drugs from Lilly, Menarini
Jan. 30, 2023 -
FDA advisers back agency plan to simplify COVID-19 vaccination
Jan. 26, 2023 -
Bristol Myers says CAR-T therapy curbed leukemia in long-running study
Jan. 26, 2023 -
Merck reports one success, one setback from late-stage Keytruda trials
Jan. 25, 2023 -
Finch to lay off 95% of staff, scrap microbiome drug study
Jan. 24, 2023 -
FDA weighs shift in COVID vaccination strategy
Jan. 23, 2023 -
FDA rejects Lilly Alzheimer’s drug, citing insufficient data
Jan. 20, 2023 -
Editas, in next restructuring step, to sell cell therapy work to Shoreline
Jan. 19, 2023 -
Large study of J&J’s HIV vaccine stopped after shot found ineffective
Jan. 18, 2023 -
5 questions facing gene therapy in 2023
Jan. 12, 2023 -
JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas
Jan. 10, 2023 -
New Biogen CEO seeks to ‘redefine’ company after challenging year
Jan. 10, 2023 -
Editas to cut jobs, narrow research focus in restructuring
Jan. 9, 2023 -
Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting
Jan. 9, 2023 -
5 FDA decisions to watch in the first quarter
Jan. 9, 2023 -
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
Jan. 6, 2023 -
Bluebird bolsters balance sheet with sale of second regulatory fast pass
Jan. 6, 2023 -
FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022
Jan. 3, 2023 -
Disappearing IPOs, building startups and closing deals: Views from an up-and-down year in biotech
Jan. 3, 2023 -
Merck builds out cancer drug pipeline with Kelun-Biotech deal
Dec. 22, 2022 -
Doubts around cancer drug target persist after Gilead, Arcus study results offer ‘mixed picture’
Dec. 20, 2022 -
FDA lifts hold on Bluebird’s sickle cell gene therapy
Dec. 19, 2022 -
Third Harmonic halts study of lead drug over safety risk
Dec. 15, 2022 -
Kymera shares jump on Sanofi’s decision to advance protein-degrading drug
Dec. 14, 2022 -
Mirati’s KRAS-blocking cancer drug approved by FDA
Dec. 13, 2022